Zearalenone (ZON) is a nonsteroidal estrogen-like mycotoxin produced by *Fusarium* species \[[@r7]\]. ZON has been shown to disrupt reproductive processes by mimicking the action of 17β-estradiol \[[@r42]\]. ZON is a common contaminant of grains such as corn and wheat worldwide \[[@r1], [@r26]\]. Due to its high thermal stability, ZON is not degraded by heat treatment during processing, resulting in reports of ZON contamination of foods produced from grains \[[@r51]\]. ZON contamination of livestock feeds is also a problem, particularly feeds for pigs.

ZON primarily affects the reproductive organs in mammals, resulting in reproductive disorders such as uterine hypertrophy, vulva vaginitis, infertility, and miscarriage \[[@r56]\]. Delay in reaching sexual maturity and disruption of implantation have been demonstrated experimentally in rodents treated with ZON \[[@r24], [@r54]\]. After oral exposure to ZON, the mycotoxin is rapidly absorbed in the gastrointestinal tract. ZON uptake is estimated to be 80--85%, and the mycotoxin and its modified forms can be detected in blood after administration \[[@r35]\]. ZON and its major derivatives are shown in [Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Schematic representation of the zearalenone metabolic pathway. Zearalenone (ZON) metabolism in mammals involves reduction catalyzed by hydroxysteroid dehydrogenase (HSDs), and conjugation catalyzed by UDP-glucuronosyltransferase (UGT). The plus sign indicates the relative estrogenic potency of the compound. The order is α-zearalanol (α-ZAL) \>α-zearalenol (α-ZOL) \>β-zearalanol (β-ZAL) \>ZON \>β-zearalenol (β-ZOL). \[[@r33]\].

ZON is metabolized to α- and β-zearalenol (ZOL) via enzymatic reactions mediated by 3α- and 3β-hydroxy-5-steroid dehydrogenases (HSDs). The resultant α- and β-ZOL are metabolized via double bond reduction to α- and β-zearalanol (ZAL), respectively. In an alternative pathway, ZON is reversibly reduced to zearalanone (ZAN) \[[@r33], [@r36]\]. These metabolites are reactive and exhibit more-potent estrogenic activity than ZON (relative estrogen potency: α-ZAL \>α-ZOL \>β-ZAL \>ZON \>β-ZOL) \[[@r17], [@r33]\]. Activated ZON derivatives undergo conjugation reactions catalyzed by UDP-glucuronosyltransferase (UGT) 1A1 and UGT1A8 \[[@r40]\]. The resulting glucuronides have low estrogenic activity and are eliminated from the body via the urine or feces \[[@r10], [@r28], [@r33]\]. The alternative metabolism of ZON (i.e., metabolic activation and conjugation) is associated with various potential adverse reproductive effects. To elucidate the mechanism of ZON-induced adverse effects on target organs, therefore, it is essential to clarify the metabolism and disposition of ZON during passage through the gastrointestinal tract.

Binder *et al.* suggested that biotransformation of ZON occurs in the intestinal wall during absorption \[[@r2]\]. However, details regarding the actual and dynamic behavior of the compound during absorption within the intestinal wall remain unclear. Because there are gender differences in the effects of ZON, especially reproductive disorders during pregnancy \[[@r24]\], we used a rat everted-intestine model to examine the metabolism and disposition of ZON, focused on gender and pregnancy differences, in the intestine, which functions as the first barrier through xenobiotic metabolism. In this rat everted-intestinal model, it is possible to track the mucosal excretion and serosal transport of compounds over time by site of the intestine \[[@r13]\].

MATERIALS AND METHODS {#s1}
=====================

Chemicals
---------

ZON was purchased from Funakoshi Co. (Tokyo, Japan); high-performance liquid chromatography (HPLC)-grade methanol was purchased from Wako Pure Chemical Industries (Osaka, Japan); and β-glucuronidase was purchased from Sigma-Aldrich (St. Louis, MO, USA). Zearalenone glucuronide (ZON-GA) and zearalenol glucuronide (ZOL-GA), purified from rat bile after perfusion of the liver with ZON, were quantified by HPLC using the difference between β-glucuronidase--treated and untreated samples and used as standards \[[@r14]\].

Ethics statement
----------------

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the U.S. National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Rakuno Gakuen University (permit number: VH18A15). All surgeries were performed under isoflurane anesthesia, and every effort was made to minimize animal suffering.

Animals
-------

Male (330--400 g), nonpregnant female (240--280 g), or pregnant female (270--340 g at gestation day 18--19) Sprague-Dawley rats (8 to 10 weeks old) were purchased from Sankyo Lab Co. (Tokyo, Japan) and used in all experiments. The rats were fed, housed, and allowed to adapt to their environment for 1 week before they were used in experiments. A total of 18 rats were used (6 males, 6 nonpregnant females, and 6 pregnant females).

Preparation of everted intestine
--------------------------------

Krebs Ringer's bicarbonate buffer (NaCl, 110 mM; KCl, 5 mM; MgCl~2~, 1.2 mM; CaCl~2~, 2.5 mM; NaHCO~3~, 25 mM and glucose, 10 mM) was used in all experiments. The solution was aerated with 95% O~2~/5% CO~2~, and the pH was adjusted to 7.4. After euthanasia by exsanguination under anesthesia, the jejunum, ileum, and colon were collected from each animal. The bowels were excised and prepared according to a modification of a previously described segmentation and eversion method \[[@r15]\]. Briefly, with the exception of the duodenum, the excised small intestine was lavaged and divided into three sections of equal length. The distal portion of each section was excised and trimmed to 10 cm and designated as segments I, II, and III in distal order, with segment I from the jejunum and segment III from the distal ileum ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Schematic illustration of the everted intestine model. (A) The small intestine, excluding the duodenum, was divided into three equal parts, and the distal part was excised and the length adjusted to 10 cm. The parts were then designated I, II, and III in distal order. In the same manner, the colon was excised and adjusted to 10 cm, taken from the distal end. (B) The everted intestine was affixed to a polyethylene tube. Serosal buffer was circulated at 5 m*l*/min using a pump. Zearalenone (10 *µ*M) was added to the mucosal buffer. The water temperature was maintained at 37°C, and the tissue was aerated with 95% O~2~/5% CO~2~.). In the same manner, the colon (segment IV) was excised, washed, and trimmed to a final segment length of 10 cm taken from the distal end.

The four trimmed segments were turned inside out and affixed to a polyethylene tube containing mucosal buffer solution (25 m*l*). Serosal buffer solution (25 m*l*) was pumped through the everted bowels using a tube pump MP-32N (EYELA, Tokyo, Japan) at 5 m*l*/min via polyethylene tubes ([Fig. 2B](#fig_002){ref-type="fig"}). ZON was added to the mucosal buffer solution at a concentration of 10 *µ*M, and reaction products were collected independently from the serosal and mucosal sides at 0, 20, 40, and 60 min after the addition of each compound. In this rat everted-intestinal model as described, sufficient metabolic kinetics could not be analyzed when the substrate concentration was below this level \[[@r13]\]. Moreover, this level of ZON is known not to affect cell viability in experiments *in vitro* experiment \[[@r42]\].

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of reaction products
---------------------------------------------------------------------------------------

Mucosal and serosal samples were filtered using a disposable disk filter (HLC-DISK3; Kanto Chemical Co.) and stored at −80°C until analysis. The samples were then analyzed using an LC-MS/MS system (Shimadzu, Ktoto, Japan) equipped with an electrospray ionization source and operated in negative mode. Mobile phases A and B consisted of methanol/water/acetic acid (5:95:0.05) with 10 mM ammonium acetate and 100% methanol, respectively. Gradient elution was performed as follows: 0--8 min (0--100% B), 8--10 min (100% B). Samples were resolved on a Triart C18 reversed-phase column (2.1 × 150 mm; YMC Co., Tokyo, Japan) and detected using multiple reaction monitoring mode. The precursor and product ions are shown in [Table 1](#tbl_001){ref-type="table"}Table 1.Optimized multiple reaction monitoring parametersAnalyte*m/z*RT ^a)^ (min)CE ^b)^ (V)ZearalenoneZON317\>2737.5821ZearalanoneZAN319\>2057.5223α-Zearalenolα-ZOL319\>1607.5032β-Zearalenolβ-ZOL319\>1607.3032α-Zearalanolα-ZAL321\>2777.4124β-Zearalanolβ-ZAL321\>2777.2424Zearalenone glucuronideZON-GA493\>1756.5719α-Zearalenol glucuronideα-ZOL-GA495\>3196.6229β-Zearalenol glucuronideβ-ZOL-GA495\>3196.3229Zearalenone diglucuronideZON-GA/GA669\>4935.7523a) RT, retention time; b) CE, collision energy.. ^13^C-ZON was used as an internal standard to quantify ZON and its derivatives.

Statistical analysis
--------------------

All data are expressed as the mean ± S.D. of six independent experiments. Mann-Whitney *U* test was applied to compare the quantitative variables by JMP 14.2 (SAS institute, Japan). In all the statistical tests, differences were considered significant if the *P* value was equal to or less than 0.05.

RESULTS {#s2}
=======

Zearalenone absorption and transport
------------------------------------

Upon application of ZON (10 *µ*M) to the mucosal side of the everted intestine, the fluid concentration of ZON decreased over the incubation period. The rate of disappearance of ZON from the mucosal compartment was estimated at approximately 100--200 nmol/hr in all segments ([Fig. 3](#fig_003){ref-type="fig"}Fig. 3.Absorption and disposition of zearalenone in rat everted intestine. Upper graph shows the amount of zearalenone (ZON) that disappeared from the mucosal side within 60 min of incubation. ZON (10 *µ*M) was added to the mucosal buffer solution of each segment. The amount of ZON was determined by subtracting the final amount of ZON in the mucosal buffer solution after a 60-min incubation. I, II, and III indicate the intestinal sites in distal order from the ligament of Trietz, and IV indicates the colon. Bottom graph shows the amount of unconjugated ZON transported to the serosal side within 60 min of incubation. ZON was added to the mucosal buffer solution of each segment at a concentration of 10 *µ*M. Segments I, II, and III are distal from the jejunum and ileum, and IV is the colon. \**P*\<0.05, \*\* *P*\<0.01.). In male and pregnant female rats, the disappearance tended to be diminished in the distal segment of the small intestine (segment III), however the disappearance of ZON was almost the same at any parts of the female rat intestinal segments.

On the serosal side of the everted intestine, a small amount of ZON was detected. The amount of ZON transported from the mucosal side to the serosal side was extremely low (approximately 2 nmol over 60 min of incubation) even in the distal colon, where the highest absorption of ZON was observed ([Fig. 3](#fig_003){ref-type="fig"} and [Supplementary Fig. 1A](#pdf_001){ref-type="supplementary-material"}).

Absorption and excretion of ZON metabolites
-------------------------------------------

The present data demonstrate the transport of a small amount of ZON from the mucosal side to the serosal side of the everted intestine, despite the considerable amount of ZON absorbed from the mucosal fluid ([Fig. 3](#fig_003){ref-type="fig"}). In a recent study, ZON was shown to be metabolized to ZON-GA, α-ZOL, β-ZOL, α-ZOL-GA, β-ZOL-GA, ZON-GA, and ZAN \[[@r33]\]. Therefore, the excretion of ZON metabolites from the intestinal segments was examined.

After 60 min of incubation, α-ZOL, ZON-GA, and α-ZOL-GA were detected in the mucosal and serosal buffers and quantified. ZAN, β-ZOL, β-ZOL-GA, and zearalenone diglucuronide were also detected, but the amounts were too low to quantify.

Excretion of α-ZOL (which is reduced at the 7α position of ZON by HSDs) to the mucosal side was observed in each segment. α-ZOL mucosal excretion tended to be higher in the male proximal intestine (segment I) and in male and pregnant female distal intestine (segments III and IV), but the amount was very small, at most approximately 0.3 nmol ([Fig. 4](#fig_004){ref-type="fig"}Fig. 4.α-Zearalenol in rat everted intestine. The amount of α-zearalenol (α-ZOL) excretion to the mucosal side (top graph) and transported to the serosal side (bottom graph) within 60 min of incubation. Zearalenone was added to the mucosal buffer solution of each segment at a concentration of 10 *µ*M. Segments I, II, and III are from the jejunum and ileum in distal order, and IV is the colon. and [Supplementary Fig. 1B](#pdf_001){ref-type="supplementary-material"}). In contrast, α-ZOL transport to the serosal side reached a maximum of approximately 0.05 nmol in the colon, an amount that was even less than observed with mucosal excretion; α-ZOL transport to the mucosal side was approximately 6 times greater than transport to the serosal side ([Fig. 4](#fig_004){ref-type="fig"} and [Supplementary Fig. 1C](#pdf_001){ref-type="supplementary-material"}).

Most of the absorbed ZON was not transported to the serosal side in its unmodified form nor excreted or transported as reduced α-ZOL. Therefore, we investigated the possibility that ZON was conjugated in the intestine. In all intestinal segments, ZON-GA and α-ZOL-GA, the glucuronidated forms of ZON and α-ZOL, were detected in large amounts. ZON-GA mucosal excretion reached a maximum of 85.39 nmol in the pregnant female proximal intestine and a minimum of 22.55 nmol in the female colon ([Fig. 5](#fig_005){ref-type="fig"}Fig. 5.Glucuronidation of zearalenone in rat everted intestine. The amount of zearalenone (ZON) glucuronidated and excreted to the mucosal side (top graph) and transported to the serosal side (bottom graph) within 60 min of incubation. ZON was added to the mucosal buffer solution of each segment at a concentration of 10 *µ*M. Segments I, II, and III are from the jejunum and ileum in distal order, and IV is the colon. and [Supplementary Fig. 1D](#pdf_001){ref-type="supplementary-material"}). In contrast, ZON-GA serosal transport reached a maximum of 49.94 nmol in the female colon and a minimum of 1.64 nmol in the female proximal intestine ([Fig. 5](#fig_005){ref-type="fig"} and [Supplementary Fig. 1E](#pdf_001){ref-type="supplementary-material"}). The maximum α-ZOL-GA mucosal excretion was 60.02 nmol in the pregnant female proximal intestine, and the minimum mucosal excretion was 20.09 nmol in the female colon ([Fig. 6](#fig_006){ref-type="fig"}Fig. 6.Glucuronidation of α-zearalenol in rat everted intestine. The amount of α-zearalenol (α-ZOL) glucuronidated and excreted to the mucosal side (top graph) and transported to the serosal side (bottom graph) within 60 min of incubation. Zearalenone was added to the mucosal buffer solution of each segment at a concentration of 10 *µ*M. Segments I, II, and III are from the jejunum and ileum in distal order, and IV is the colon. and [Supplementary Fig. 1F](#pdf_001){ref-type="supplementary-material"}). By comparison, the maximum α-ZOL-GA serosal transport was 36.15 nmol in the pregnant female colon, and the minimum serosal transport was 2.84 nmol in the female proximal intestine ([Fig. 6](#fig_006){ref-type="fig"} and [Supplementary Fig. 1G](#pdf_001){ref-type="supplementary-material"}). Interestingly, the maximum amounts of ZON-GA and α-ZOL-GA were secreted to the mucosal side of the intestine (segments I\~III), whereas in the colon, mucosal secretion of these glucuronides was reduced ([Figs. 5](#fig_005){ref-type="fig"} and[6](#fig_006){ref-type="fig"}). The lowest ZON-GA and α-ZOL-GA secretion to the serosal side occurred in the proximal small intestine and increased with progression distally to the colon.

Fate of ZON at 60-min post-application
--------------------------------------

The total balance of metabolism and transport after 60 min of incubation with ZON (10 *µ*M) was examined ([Fig. 7](#fig_007){ref-type="fig"}Fig. 7.Fate of zearalenone during a 60-min incubation in rat everted intestine. Total decrease in mucosal zearalenone (ZON) during a 60-min incubation is depicted as the sum total of the fraction column in each intestinal segment. ZON, zearalenone transported to the serosal side; α-ZOL, total α-zearalenol transported to the serosal side and secreted to the mucosal side; ZON-GA, total zearalenone glucuronide transported to the serosal side and secreted to the mucosal side; α-ZOL-GA, total α-zearalenol glucuronide transported to the serosal side and secreted to the mucosal side; Unknown fate, zearalenone of unknown fate. Segments I, II, and III are distal from the jejunum and ileum, and IV is the colon.). Most of the absorbed substrate was recovered (\>80%) in all segments in male, female, and pregnant females, with the exception of male small intestine segments I and II and pregnant female colon segment IV ([Fig. 7](#fig_007){ref-type="fig"}). Absorbed ZON was rapidly metabolized to α-ZOL, ZON-GA, and α-ZOL-GA, based on the observation that absorbed ZON did not remain completely in its unmodified form in any of the intestine segments. Furthermore, each glucuronide was largely excreted to the mucosal side, but in the distal intestine, approximately half of each glucuronide was transported to the serosal side ([Figs. 5](#fig_005){ref-type="fig"} and[6](#fig_006){ref-type="fig"}).

DISCUSSION {#s3}
==========

ZON introduced orally must pass through the intestine before reaching the target organs, such as the reproductive system. To elucidate the mechanism responsible for the adverse effects of ZON, it is essential to clarify the fate of the compound in the intestine. However, details regarding the disposition of ZON during transport to the target organs remain unclear. In this study, we used a rat everted intestine model to elucidate the fate of ZON in the intestine, which due to metabolic activity functions as the first barrier to xenobiotics.

Our results indicate that most ZON absorbed from the mucosal side is reduced or glucuronidated in the intestinal cells. A small amount of unconjugated α-ZOL was detected, but ZAN and α-/β-ZAL were not detected. It can be inferred that ZON is readily converted to ZOL in the rat intestine. ZON has also been reported to be hydroxylated primarily by CYP3A subfamily enzymes \[[@r5], [@r41]\]. The CYP3A subfamily includes major drug-metabolizing enzymes in the intestine, and it was reported that CYP3A is also expressed in rat intestine \[[@r11], [@r23], [@r31]\], but OH-ZON was not found in our results. ZON is also known to be converted to ZOL by HSDs \[[@r29]\]. Since high levels of 3α-HSD mRNA were found in small intestine and colon \[[@r27]\], it seems that 3α-HSD is also involved in the ZON reduction reaction in the intestine. The examinations of the contribution rate of HSDs to ZOL metabolism represent interesting topics for future research. In our data, mucosal excretion of α-ZOL was low in each intestinal segment, but serosal transport was even lower. These data indicate that each intestine segment hardly passes α-ZOL to the serosal side. Interestingly, the almost complete absence of detection of α-ZOL suggests that α-ZOL is immediately glucuronidated. In other words, by inactivating ZON via glucuronidation, the intestine functions as a barrier against absorption of foreign substances. Because the glucuronidation of ZON was particularly extensive in all intestinal segments ([Fig. 7](#fig_007){ref-type="fig"}), UGT expression and activity are high in the intestine, and ZON and α-ZOL likely undergo immediate glucuronidation. This suggests that the intestine functions as a barrier to ZON exposure. In general, enzymes of the UGT2B family glucuronidate steroid hormones \[[@r50]\]. UGT1A1, 1A7, 1A8, and 2A3 are highly expressed in the rodent intestine, especially the proximal intestine \[[@r4], [@r38]\]. A study using human liver and intestinal microsomes reported that UGT1A1, 1A3, 1A8, and 2B7 exhibited high activity against ZON \[[@r40]\]. Ugt2b mRNA accounts for approximately 80% of total Ugt mRNA in the rat liver, whereas Ugt1a mRNA accounts for almost 90% of total Ugt mRNA in the rat small intestine \[[@r25]\]. UGT1A1 and 1A8 thus appear to be the most promising candidates responsible for ZON glucuronidation in the intestine.

More than half of the ZON absorbed in the small intestine in the present study was glucuronidated, and most of it was excreted to the mucosal side. This is consistent with the small intestinal defense mechanism against bisphenol A, an endocrine-disrupting chemical known to have estrogenic effects similar to ZON \[[@r13], [@r16]\]. These data suggest that the proximal intestine plays a highly protective role, restricting the dissemination of xenobiotics and inactivating them via glucuronidation, thus restricting exposure to the active substances to the middle and distal parts of the intestines. ATP-dependent transporters, namely multidrug resistance associated proteins (MRPs), are known to be capable of mediating transmembrane excretion of a wide range of amphiphilic compounds, including estrogens and glucuronides \[[@r37], [@r52]\]. MRP2, which is localized in the apical domain of enterocytes, is distributed in the proximal intestine in rats, and MRP3, which is localized in the basal domain, is distributed in the colon \[[@r21], [@r32], [@r46]\]. Interestingly, in this study, the excretion of ZON-GA and α-ZOL-GA in the apical direction and transport in the basal direction were consistent with the respective localization and distribution patterns of MRP2 and MRP3 in the rat intestine. From these data, we speculate that ZON-GA and α-ZOL-GA are excreted and transported in the intestine by MRP2 and MRP3, respectively ([Fig. 8](#fig_008){ref-type="fig"}Fig. 8.Schematic figure of our hypothesis of intestine region-dependent metabolism and excretion of metabolites. Most of the zearalenone (ZON) absorbed in the intestine is glucuronidated to zearalenone glucuronide (ZON-GA) or α-zearalenol glucuronide (α-ZOL-GA) by UDP-glucuronosyltransferase (UGT). Then, in the proximal intestine, it is likely to be excreted mainly to the mucosal side via multidrug resistance associated proteins 2 (MRP2), while in the distal intestine, it is likely to be mainly transported to the serosal side via MRP3. Some slight ZON may be transported to the serosal side in its unmodified form. It is possible that some ZON and its glucuronide absorbed in the distal colon may circulate systemically without passing through the liver.).

It has been shown that the entire intestine functions as a barrier to xenobiotics, but there is also a risk of exposure. In this study, ZON and its metabolites were also transported to the serosal side. The level of ZON serosal transport observed in each intestinal segment was extremely low, and this seems not to be problematic because the experiment was performed using a large amount of ZON. However, compared with ZON, the amount of glucuronidated form transported to the serosal side was quite high, approximately 10 times greater in the small intestine and approximately 20 times greater in the colon. Some of the conjugates transported into the blood are known to be distributed to local organs without being excreted \[[@r16], [@r34]\]. Conjugates transported to local organs can reportedly cause adverse effects due to deconjugation and reactivation within the local organs. In our study, the serosal transport of ZON-GA and α-ZOL-GA was particularly high in the colon. Anatomically, some of the compounds absorbed in the distal colon do not pass through the liver and circulate systemically without the first effect of the liver ([Fig. 8](#fig_008){ref-type="fig"}). Therefore, it is possible that most of the ZON-GA and α-ZOL-GA absorbed in the colon circulate through the body and are distributed in local organs, where they could be reactivated by deconjugation. In addition, the serosal transport of α-ZOL-GA was comparable to that of ZON-GA. The estrogenic activity of α-ZOL is three times more potent than that of ZON \[[@r30]\]. This suggests that the blood absorption of α-ZOL-GA in the colon plays an important role in the mechanism by which orally ingested ZON disrupts the endocrine system.

ZON-GA and α-ZOL-GA excreted to the mucosal side in the proximal jejunum are thought to flow into the distal intestine with the digestive contents. ZON is also excreted in the bile after glucuronidation in the liver \[[@r53]\]. In general, glucuronides are likely to enter the enterohepatic circulation \[[@r39]\], suggesting that large amounts of ZON-GA and α-ZOL-GA flow into the distal intestine. In the colon, glucuronides can be deconjugated by enterobacterial β-glucuronidase \[[@r43]\]. Irinotecan, an antineoplastic drug, is metabolized in the body by carboxylesterase to the active substance 7-ethyl-10-hydroxycamptothecin (SN-38). Thus, SN-38 exhibits antineoplastic activity \[[@r12]\]. SN-38 is glucuronidated by UGT in the liver and excreted in the bile as an inactive substance, SN-38 glucuronide (SN-38-GA) \[[@r45]\]. SN-38-GA excreted in bile is reportedly deconjugated by enterobacterial β-glucuronidase and reactivated \[[@r20]\]. Reactivated SN-38 can be resorbed in the distal intestine and damage mucosal tissues \[[@r49]\]. The behavior pattern of irinotecan in the body can be applied to ZON, with ZON-GA and α-ZOL-GA flowing to the distal intestine and being reactivated by deconjugation, with a risk of eventual reabsorption in the colon.

In this study, the rate of recovery of absorbed ZON in the proximal intestine was low. Ingestion of low doses of ZON in immature gilts reportedly leads to accumulation of ZON in the proximal intestine immediately after exposure \[[@r55]\]. As in pigs, it is possible that ingested ZON accumulates in the proximal jejunum in rats, but further investigation is necessary to confirm this possibility. Compared with the male distal intestine and the female proximal intestine, the male proximal intestine absorbed more ZON from the mucosal side, and there was a large amount of undetected material, indicating unknown fate. This suggests that ingested ZON follows different metabolic pathways in males and females, which could be associated with sex-specific differences in toxicity. In our results, although there were some slight gender differences in the absorption of ZON in the intestine, there was no significant difference in the kinetics of ZON-GA and α-ZOL-GA, the main metabolite of ZON in the intestine, between male and female, and between pregnancy and non-pregnancy. It is known that the expression in the intestine of CYP3A, which is presumed to be involved in the reduction of ZON, is not different by gender \[[@r22]\]. In addition, transcriptional regulation of the UGT1A genes in jejunum and colon has been reported to be suppressed through estrogen receptor α (ERα) \[[@r18]\], but it is known that gender differences in UGT expression vary with species and strains \[[@r25]\]. It is also known that few Ugt genes are affected by pregnancy \[[@r48]\]. On the other hand, the expression in the liver of the enzymes involved in the metabolism of ZON and the transporters related to the transport of ZON metabolites has been reported to differ depending on the gender and presence or absence of pregnancy \[[@r8], [@r22], [@r25], [@r48]\]. From these facts, the difference in ZON kinetics between male and female, and between pregnancy and non-pregnancy, is more likely to be affected by liver metabolism than intestine. Elucidation of the detailed metabolic kinetics of ZON in the liver, focusing on gender and pregnancy status, is interesting topic for future research.

The intestine is the first barrier to orally ingested xenobiotics. In investigating the effects of xenobiotics, it is important to track the fate of the target compound in the intestine before it enters the bloodstream. The present study revealed that ZON is metabolized to an inactive metabolite, ZON-GA or α-ZOL-GA, in the proximal intestine and then excreted to the intestinal lumen ([Fig. 8](#fig_008){ref-type="fig"}). This confirms that the intestine plays a significant defensive role against the dissemination of ZON in the body. However, the metabolites ZON-GA and α-ZOL-GA are absorbed into the blood primarily in the colon, suggesting that there is a risk of transport to local target organs. It would be interesting to investigate how ZON-GA and α-ZOL-GA are subsequently metabolized and distributed after being absorbed into the blood in the intestine. Fully elucidating the mechanism of ZON toxicity is thus an important issue for future research. Additionally, ZON is known to be metabolized by plants and fungi, undergoing glycoside or sulfate conjugation \[[@r19], [@r44]\]. These externally conjugated compounds are known as masked mycotoxins, and their presence as contaminants has been reported in food and feed products \[[@r3], [@r6], [@r47]\]. Although masked mycotoxins are harmless to mammals, considerable care is required to prevent their conversion to the parental mycotoxins after ingestion and further biotransformation into unidentified metabolites \[[@r9]\]. Future research should also investigate the behavior of these compounds.
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